Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vandetanib

FDA-approved product (tablet, oral), marketed as Caprelsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vandetanib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vandetanib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vandetanib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

    NCT00995007 · start 2009-09

    Registered record
    Registry ID
    NCT00995007
    Conditions
    Glioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Oligoastrocytoma
    Interventions
    ZD6474 (Vandetanib); Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2015-12
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma Multiforme; Gliosarcoma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma +1 more
    InterventionZD6474 (Vandetanib); Carboplatin
    PhasePhase 2
    Registry statusCompleted

  • Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

    NCT00807170 · start 2009-05

    Registered record
    Registry ID
    NCT00807170
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    ZD6474 (Vandetanib); Whole Brain Radiotherapy (WBRT); ZD6474; ZD6474
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2009-05
    Completion
    2010-08
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionZD6474 (Vandetanib); Whole Brain Radiotherapy (WBRT); ZD6474; ZD6474
    PhasePhase 1
    Registry statusTerminated

  • A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

    NCT00923247 · start 2009-02-19

    Registered record
    Registry ID
    NCT00923247
    Conditions
    Medullary Thyroid Carcinoma
    Interventions
    Bortezomib; Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2009-02-19
    Completion
    2016-12-09
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Carcinoma
    InterventionBortezomib; Vandetanib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Study of GemOx and Vandetanib in Advanced Solid Malignancy

    NCT00660725 · start 2009-02

    Registered record
    Registry ID
    NCT00660725
    Conditions
    Advanced Incurable Solid Malignancy
    Interventions
    Vandetanib; Gemcitabine; Oxaliplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-12
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Incurable Solid Malignancy
    InterventionVandetanib; Gemcitabine; Oxaliplatin
    PhasePhase 1
    Registry statusCompleted

  • Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

    NCT00745732 · start 2008-10-09

    Registered record
    Registry ID
    NCT00745732
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    ZD6474 (ZACTIMA); Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-10-09
    Completion
    2012-09
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionZD6474 (ZACTIMA); Radiation Therapy
    PhasePhase 1
    Registry statusTerminated

  • Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

    NCT00753675 · start 2008-10

    Registered record
    Registry ID
    NCT00753675
    Conditions
    Biliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma
    Interventions
    ZD6474, Vandetanib; ZD6474, Vandetanib; Gemcitabine; Placebo matching ZD6474
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2012-09
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Cancer; Gallbladder Cancer; Cancer Of The Extrahepatic Bile Duct; Ampullary Carcinoma
    InterventionZD6474, Vandetanib; ZD6474, Vandetanib; Gemcitabine; Placebo matching ZD6474
    PhasePhase 2
    Registry statusCompleted

  • Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy

    NCT00777179 · start 2008-10

    Registered record
    Registry ID
    NCT00777179
    Conditions
    NSCLC
    Interventions
    Vandetanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-10
    Completion
    2011-12
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionVandetanib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

    NCT00821080 · start 2008-10

    Registered record
    Registry ID
    NCT00821080
    Conditions
    Glioblastoma
    Interventions
    Sirolimus; Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-10
    Completion
    2015-02
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionSirolimus; Vandetanib
    PhasePhase 1
    Registry statusCompleted

  • S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

    NCT00937417 · start 2008-09

    Registered record
    Registry ID
    NCT00937417
    Conditions
    Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    docetaxel; vandetanib; proteomic profiling; laboratory biomarker analysis; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2008-09
    Completion
    2009-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer +1 more
    Interventiondocetaxel; vandetanib; proteomic profiling; laboratory biomarker analysis +1 more
    PhasePhase 1
    Registry statusWithdrawn

  • A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery

    NCT01183559 · start 2008-08-07

    Registered record
    Registry ID
    NCT01183559
    Conditions
    Cancer of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Cancer of the Stomach
    Interventions
    Vandetanib; 5 Fluorouracil (FU); Carboplatin; Paclitaxel; External Beam Radiation Therapy (RT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-08-07
    Completion
    2011-08
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Cancer of the Stomach
    InterventionVandetanib; 5 Fluorouracil (FU); Carboplatin; Paclitaxel +1 more
    PhasePhase 1
    Registry statusCompleted

  • Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib

    NCT00667147 · start 2008-03

    Registered record
    Registry ID
    NCT00667147
    Conditions
    Solid Tumors
    Interventions
    Weekly Abraxane and Daily Vandetanib; Abraxane every three weeks and daily vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2008-03
    Completion
    2014-06
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionWeekly Abraxane and Daily Vandetanib; Abraxane every three weeks and daily vandetanib
    PhasePhase 1
    Registry statusCompleted

  • Phase II Study of Vandetanib in Individuals With Kidney Cancer

    NCT00566995 · start 2008-02-07

    Registered record
    Registry ID
    NCT00566995
    Conditions
    Renal Cancer; Von Hippel Lindau
    Interventions
    ZACTIMA (Vandetanib) (ZD6474)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02-07
    Completion
    2015-03
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cancer; Von Hippel Lindau
    InterventionZACTIMA (Vandetanib) (ZD6474)
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer

    NCT00659438 · start 2008-02

    Registered record
    Registry ID
    NCT00659438
    Conditions
    Prostate Cancer
    Interventions
    ZD6474 (Vandetanib); Bicalutamide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2011-07
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionZD6474 (Vandetanib); Bicalutamide; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

    NCT00481845 · start 2008-01

    Registered record
    Registry ID
    NCT00481845
    Conditions
    Breast Cancer
    Interventions
    Vandetanib; Anastrozole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2009-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionVandetanib; Anastrozole
    PhasePhase 2
    Registry statusTerminated

  • Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

    NCT00514046 · start 2007-07-20

    Registered record
    Registry ID
    NCT00514046
    Conditions
    Medullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2007-07-20
    Completion
    2020-11-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Carcinoma; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B
    InterventionVandetanib
    PhasePhase 1 / Phase 2
    Registry statusCompleted